<DOC>
	<DOCNO>NCT01214109</DOCNO>
	<brief_summary>To establish bioequivalence steady state : 1 ) 0.375 mg pramipexole extend release tablet q.d . fast status versus 0.125 mg pramipexole Immediate release tablet t.i.d . fast status 2 ) 1.5 mg pramipexole extend release tablet q.d . fast status versus 0.5 mg pramipexole Immediate release tablet t.i.d . fast status To investigate dose proportionality pharmacokinetics parameter : 1 ) pramipexole extend release dosage 0.375 1.5 mg q.d .</brief_summary>
	<brief_title>Multiple Dose Bioequivalence Study Pramipexole Extended Release Chinese Healthy Male Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Pramipexole</mesh_term>
	<criteria>Inclusion criterion : 1 . Healthy male accord follow criterion : Based upon complete medical history , include physical examination , vital sign ( blood pressure , pulse rate ) , 12lead electrocardiogram , clinical laboratory test 2 . Age old equal 18 Age young equal 40 year 3 . Body Mass Index large equal 19 Body Mass Index less equal 24kg/m2 4 . Signed date write informed consent prior admission study accordance Good Clinical Practice local legislation . Exclusion criterion : 1 . Any finding medical examination ( include Pulse Rate electrocardiogram ) deviate normal clinical relevance 2 . Any evidence clinically relevant concomitant disease 3 . Gastrointestinal , hepatic , renal , respiratory , cardiovascular , metabolic , immunological hormonal disorder 4 . Surgery gastrointestinal tract ( except appendectomy ) 5 . Diseases central nervous system ( epilepsy ) psychiatric disorder neurological disorder 6 . History relevant orthostatic hypotension , faint spell blackout . 7 . Chronic relevant acute infection 8 . History relevant allergy/hypersensitivity ( include allergy drug excipients ) 9 . Intake drug long halflife ( long 24 hour ) within least one month le 10 halflives respective drug prior administration trial 10 . Use drug might reasonably influence result trial 7 day start drug administration study study period 11 . Participation another trial investigational drug within one month prior administration trial 12 . Smoker ( 10 cigarette 3 cigar 3 pipes/day ) 13 . Inability refrain smoke trial day 14 . Alcohol abuse ( 40 g/day ) 15 . Drug abuse 16 . Blood donation ( 100 mL within four week prior administration trial ) 17 . Excessive physical activity ( within one week prior administration trial ) 18 . Any laboratory value outside reference range clinical relevance 19 . Any positive result hepatitis B surface antigen ( HBsAg ) , anti hepatitis B core ( HBc ) antibody , anti hepatitis C virus ( HCV ) antibodies human immunodeficiency virus ( HIV ) test Exclusion criterion specific study : 20 . Hypersensitivity pramipexole dopamine agonists 21 . Supine blood pressure screen systolic &lt; 100 mmHg diastolic &lt; 60 mmHg , symptomatic orthostatic hypotension ( . .e . clinical symptom orthostatic hypotension associate decline &gt; =20 mmHg systolic BP decline &gt; =10 mmHg diastolic BP , one minute standing compare previous supine systolic diastolic BP obtain 5 minute quiet rest )</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>March 2014</verification_date>
</DOC>